Personalized Diagnostics Forum | Innovation Acceleration: New Drivers Shaping the Future of Personalized Medicine
Amidst a capital winter and the transmission of pressure from the secondary market to the primary market, 2022 was a year of ups and downs for China’s precision diagnosis and treatment sector, marked by both excitement and disillusionment. After years of abundant funding, exuberance, and frenzy, certain sub-sectors have entered a period of calm, with industry bubbles gradually deflating as companies focus more intently on strengthening their core competencies. Other sub-sectors, after lying dormant for many years, have stepped into the spotlight, entering a phase of capital and industrialization harvest. Still others, long constrained by challenges in standardized development, are being pushed by sustained high-level policy attention toward the brink of an explosive breakthrough.
Some have ridden the waves, some have broken new ground, and others have lain in wait. As we bid farewell to the ups and downs of 2022, we welcome a new year marked by vibrant growth and blossoming opportunities. What significant changes occurred in the personalized medicine industry in 2022? What emerging trends in 2023 deserve our attention? And how can we seize the new opportunities hidden behind these shifts?
In light of this, the 7th Future Healthcare Top 100 Conference has specially establishedInnovative Development of Personalized Diagnosis and TreatmentForum, bringing together industry experts, innovative enterprises, and investment institutions to jointly discuss the development of personalized diagnosis and treatment based on individual genetic profiles. This initiative aims to advance diagnostic and therapeutic technologies in the field of personalized medicine, provide patients with more efficient and cost-effective care solutions, and contribute to the realization of a Healthy China.
(1)Policy Trends: Accelerated Centralized Procurement and Standardization of LDTs
In 2022, many regions adopted a more supportive stance toward the Laboratory Developed Tests (LDT) model, while centralized procurement policies for the in vitro diagnostics (IVD) sector became more mature and expanded in scope. These policies have significantly encouraged industry innovation, yet they also impose stringent cost requirements, compelling companies to align their R&D efforts and product portfolios with policy directives and clinical realities. In light of this, the forum will invite experts to interpret relevant policies and regulations, focusing on their impact on specific industry segments.
(II)Innovative Applications: New Momentum for Differentiated Positioning and Accelerated Innovation
Technological innovation that aligns with genuine clinical needs is a significant driver of industry disruption. In the past two years, driven by upstream technological breakthroughs, lowered entry barriers, increased downstream cost pressures, and stricter regulatory oversight, the pace at which domestically produced sequencers are being launched has accelerated. On the downstream side, application scenarios andTechnologies are becoming more diversified. Companion diagnostics, infectious disease testing, genetic disorder testing, early cancer screening, and MRD detection are the primary application scenarios for precision diagnosis and treatment, with an ever-expanding range of products.Meanwhile, there are alsoClinical Mass Spectrometry, Breath Analysis Innovative technological applications in scenarios such as VOC detection, nanopore sequencing, single-cell sequencing, multiplex fluorescent immunohistochemistry, and AIinnovative products in China. New application scenarios, such as neurological disease testing and home-based testing, are also experiencing rapid development driven by technological advancements and policy support.
(3)Model Iteration: Corporate Differentiation and Opportunities in Overseas Markets
The seller’s market that emerged during the COVID-19 pandemic has not only opened channels for Chinese companies to expand overseas but also unlocked new possibilities in international markets. In the post-pandemic era, companies across various sub-sectors are targeting the vast overseas market and accelerating their global expansion. Amidst the homogenization of pan-cancer product pipelines, how can companies build differentiated advantages and achieve breakthroughs? With patient needs at the core, what is the future direction of oncology companion diagnostics? As end-user scenarios for early cancer screening become increasingly diversified, how can companies seize overseas opportunities to penetrate international markets? Addressing these current hot topics in the industry, this forum will invite representatives from enterprises and investment firms to engage in insightful discussions and exchange perspectives.
Forum Name:Personalized Diagnosis and Treatment Forum
Forum Schedule:May 5–7, 2023
Forum Location:Shanghai · Zhangjiang Science Hall
Corporate Representatives in Attendance:ChenAn Bio, Jinxiang Medicine, Jingzhi Future, Kuoran Genomics, Tianrui Diagnostics, Zhiben Medical
※ Listed in alphabetical order by company name; rankings are not sequential.
Forum Agenda Planning:
Applications of Single-Cell Technology in Drug Development and Clinical Testing Markets
How Miniaturization of Mass Spectrometry Breaks the Boundaries of Analytical Testing and Facilitates Clinical Applications
Discovery of Novel Biomarkers: Expanding the Application Space of Precision Oncology
Multiplex Fluorescence Immunohistochemistry: Best Practices for Next-Generation Molecular Pathology Applications
How Can Enterprises Achieve Differentiated Breakthroughs in Technical Products Amid a Capital Winter?
Bidding Farewell to the Era of Disordered Expansion: How Can Personalized Oncology Diagnosis and Treatment Embark on a New Chapter for the Industry?
※The proposed agenda above is for reference only; the final agenda shall be subject to on-site confirmation.
